2. Signaling Pathways
  3. PROTAC
  4. RIBOTAC

RIBOTAC

Ribonuclease-targeting Chimera

RIBOTACs are a new class of small molecules that have the potential to target diverse types of RNAs. RIBOTACs are based on small molecules that selectively bind RNAs, especially RNAs that form intricate secondary and tertiary structures. RIBOTACs are composed of an RNA-binding compound conjugated to a second small molecule that recruits and locally activates RNase L1, which preferentially cleaves RNAs with a UNN pattern (with unpaired Us). In this way, RIBOTACs recruit an active RNase L to an RNA of interest, causing its degradation.

RIBOTAC Related Products (18):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153713
    MYC-RIBOTAC 98.17%
    MYC-RIBOTAC is a nucleic acid-targeting degrader (ribonuclease-targeting chimera, RIBOTAC) that targets the MYC internal ribosome entry site (IRES). MYC-RIBOTAC contains a MYC mRNA binding component and a small molecule that recruits and locally activates RNAse L1. MYC-RIBOTAC reduces MYC mRNA and protein expression levels, induces cell apoptosis, and can be used for antitumor research. MYC-RIBOTAC consists of pre-miR-155 binder Anticancer agent 167 (HY-156839), RNA binder NCI-B16 (HY-156215), and Linker Amino-PEG4-alcohol (HY-W008005).
    MYC-RIBOTAC
  • HY-139682
    Dovitinib-RIBOTAC 2759351-68-1 99.31%
    Dovitinib RIBOTAC is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC can inhibit the metastasis of breast cancer and has anti-tumor activity.
    Dovitinib-RIBOTAC
  • HY-139682A
    Dovitinib-RIBOTAC TFA 2759351-69-2 98.35%
    Dovitinib RIBOTAC TFA is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC TFA can inhibit the metastasis of breast cancer and has anti-tumor activity.
    Dovitinib-RIBOTAC TFA
  • HY-171148
    F1-RIBOTAC 3019907-96-8
    F1-RIBOTAC is a ribonuclease-targeting chimeras (RIBOTACs). F1-RIBOTAC decreases QSOX1-a mRNA expression level in an RNase L-dependent manner. F1-RIBOTAC can be used for the research of cancer. (Pink: RNA ligand (HY-168460); Black: linker (HY-W008005); Blue: RNase L ligand (HY-168452))
    F1-RIBOTAC
  • HY-168457
    RNase L ligand 2 3025538-34-2
    RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC.
    RNase L ligand 2
  • HY-183981
    RNA binder 4
    RNA binder 4 is an RNA-binding agent that can be used for the synthesis of MJ-NR-27 (HY-183980). MJ-NR-27 is a bifunctional ribonuclease-targeting chimera (RIBOTAC) small molecule that targets NRAS mRNA containing a G-quadruplex structure, and it can be used in cancer research.
    RNA binder 4
  • HY-183980
    MJ-NR-27
    MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research.
    MJ-NR-27
  • HY-168452
    RNase L ligand 1
    RNase L ligand 1 (Compound F1-COOH) is the ligand for RNase L that can be used for synthesis of F1-RIBOTAC (HY-171148).
    RNase L ligand 1
  • HY-177030
    RNase L ligand 3 3036649-51-8
    RNase L ligand 3 is a RNase L ligand. RNase L ligand 3 can be used for synthesis of F3-PEG8-RiboTAC (HY-176259).
    RNase L ligand 3
  • HY-162504
    2'-RIBOTAC-U
    2'-RIBOTAC-U is a ribonuclease (RNase) targeting chimeras (RIBOTACs) and SARS-CoV-2 replication inhibitor. 2'-RIBOTAC-U is composed of a metabolic handle (Blue), a linker (Black) and a RNase L recruiter (Pink). RIBOTACs recruits cellular RNases to specific RNA targets, thereby leading to the degradation of these RNAs.
    2'-RIBOTAC-U
  • HY-168460
    RNA recruiter 2
    RNA recruiter 2 is a QSOX1 mRNA ligand. RNA recruiter 2 can serve as a ligand for target RNA (Ligands for Target RNA for RIBOTAC) for the development of RIBOTAC RNA degraders with antitumor activity. RNA recruiter 2 can be used for the synthesis of F1-RIBOTAC (HY-171148).
    RNA recruiter 2
  • HY-168455
    RNAse L RIBOTAC
    RNAse L RIBOTAC (compound C64) is an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. (Blue: RNA ligand (HY-168456); Black: linker (HY-130591); Pink: Rnase L ligand (HY-168457))
    RNAse L RIBOTAC
  • HY-141878
    di-Ellipticine-RIBOTAC 2767983-76-4
    di-Ellipticine-RIBOTAC is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2)exp). di-Ellipticine-RIBOTAC selectively binds the three-dimensional (3D) structure formed by r(G4C2)exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2)exp. di-Ellipticine-RIBOTAC selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2)exp. di-Ellipticine-RIBOTAC significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    di-Ellipticine-RIBOTAC
  • HY-141878A
    di-Ellipticine-RIBOTAC TFA 2767983-77-5
    di-Ellipticine-RIBOTAC TFA is a RNase recruiting chimera (RIBOTAC) degrader, capable of specifically binding and degrading expanded G4C2 RNA repeat (r(G4C2)exp). di-Ellipticine-RIBOTAC TFA selectively binds the three-dimensional (3D) structure formed by r(G4C2)exp and that recruits an endogenous ribonuclease (RNase) to cleave r(G4C2)exp. di-Ellipticine-RIBOTAC TFA selectively degrades the mutant chromosome 9 open reading frame 72 (C9orf72) allele and reduces quantities of toxic dipeptide repeat proteins (DPRs) translated from r(G4C2)exp. di-Ellipticine-RIBOTAC TFA significantly improves the pathological phenotype of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) in cells and mouse models. di-Ellipticine-RIBOTAC TFA can be used for the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    di-Ellipticine-RIBOTAC TFA
  • HY-176259
    F3-PEG8-RiboTAC
    F3-PEG8-RiboTAC is a RiboTAC that can specifically degrade the mRNA of the oncogene LGALS1. F3-PEG8-RiboTAC can induce tumor cell apoptosis and inhibit invasion. F3-PEG8-RiboTAC has anti-tumor activity and can be used in the research of tumors such as leukemia and triple-negative breast cancer. (RNase L ligand (HY-177030); RNA binder (HY-177031); Linker (HY-W019798)).
    F3-PEG8-RiboTAC
  • HY-168458
    RNA recruiter-linker 1
    RNA recruiter-linker 1 is the RNA ligand-linker part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter-linker 1 can be utilized in the synthesis of RIBOTAC.
    RNA recruiter-linker 1
  • HY-177031
    RNA binder 3
    RNA binder 3 is an RNA binder that can be used in the synthesis of RiboTAC F3-PEG8-RiboTAC (HY-176259).
    RNA binder 3
  • HY-168456
    RNA recruiter 1
    RNA recruiter 1 is the RNA ligand of RNAse L RIBOTAC (HY-168456), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter 1 can be utilized in the synthesis of RIBOTAC.
    RNA recruiter 1